ImmunityBio (IBRX) Total Current Liabilities (2014 - 2026)
ImmunityBio (IBRX) posted quarterly Total Current Liabilities of $68.0 million for Q1 2026, up 38.1% year-over-year from $49.2 million in Q1 2025, and up 10.04% quarter-over-quarter from $61.8 million in Q4 2025.
ImmunityBio (IBRX) Total Current Liabilities (2014 - 2026) Analysis & Trends
ImmunityBio (IBRX) has reported Total Current Liabilities for 13 consecutive years, with $68.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Current Liabilities rose 38.1% year-over-year to $68.0 million; the TTM figure through Mar 2026 stood at $68.0 million (up 38.1% YoY), while the FY2025 annual figure was $61.8 million, up 12.39% from the prior year.
- Total Current Liabilities grew to $68.0 million in Q1 2026 per IBRX's latest filing, from $61.8 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $613.5 million in Q2 2023 and bottomed at $49.2 million in Q1 2025.
- Historically, Total Current Liabilities has averaged $186.7 million across 5 years, with a median of $62.1 million in 2024.
- Annual changes were most pronounced in 2022 — Total Current Liabilities jumped 405.25% — and 2024, when it tumbled 90.48%.
- ImmunityBio's Total Current Liabilities stood at $500.9 million in 2022, then slumped by 88.36% to $58.3 million in 2023, then slipped by 5.73% to $54.9 million in 2024, then grew by 12.39% to $61.8 million in 2025, then increased by 10.04% to $68.0 million in 2026.
- Business Quant data shows IBRX's Total Current Liabilities at $68.0 million in Q1 2026, $61.8 million in Q4 2025, and $57.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 354.06 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4.22 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 630.93 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.51 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 438.74 Mn |
| 10 | ImmunityBio | 7.97 Bn | 7.62 Bn | 50.94 Mn | 76.73 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 76.73 Mn |
| Mar 31, 2026 | 67.95 Mn |
| Dec 31, 2025 | 61.75 Mn |
| Sep 30, 2025 | 57.13 Mn |
| Jun 30, 2025 | 50.64 Mn |
| Mar 31, 2025 | 49.21 Mn |
| Dec 31, 2024 | 54.94 Mn |
| Sep 30, 2024 | 60.96 Mn |
| Jun 30, 2024 | 62.11 Mn |
| Mar 31, 2024 | 53.76 Mn |
| Dec 31, 2023 | 58.28 Mn |
| Sep 30, 2023 | 90.32 Mn |
| Jun 30, 2023 | 613.48 Mn |
| Mar 31, 2023 | 564.95 Mn |
| Dec 31, 2022 | 500.86 Mn |
| Sep 30, 2022 | 70.84 Mn |
| Jun 30, 2022 | 376.05 Mn |
| Mar 31, 2022 | 381.01 Mn |
| Dec 31, 2021 | 369.00 Mn |
| Sep 30, 2021 | 65.41 Mn |